SLC5A2 and heart failure: SGLT2 inhibitors has shown significant efficiency in several landmark heart failure randomized clinical trials and is recommended by major guidelines (Tsutsui, 2022; Heidenreich et al., 2022; Moghaddam et al., 2023; Patel et al., 2023).